1. Repositório Institucional da UFMG
  2. Publicações Científicas e Culturais
  3. Artigo de Periódico
Please use this identifier to cite or link to this item: http://hdl.handle.net/1843/61013
Full metadata record
DC FieldValueLanguage
dc.creatorBruno Ramos Chrcanovicpt_BR
dc.creatorRoberta Rayra Martins-Chavespt_BR
dc.creatorFlávia Sirotheau Correa Pontespt_BR
dc.creatorFelipe Paiva Fonsecapt_BR
dc.creatorRicardo Santiago Gomezpt_BR
dc.creatorHélder Antônio Rebelo Pontespt_BR
dc.date.accessioned2023-11-16T21:17:50Z-
dc.date.available2023-11-16T21:17:50Z-
dc.date.issued2022-07-13-
dc.citation.volume51pt_BR
dc.citation.issue7pt_BR
dc.citation.spage603pt_BR
dc.citation.epage610pt_BR
dc.identifier.doihttps://doi.org/10.1111/jop.13334pt_BR
dc.identifier.urihttp://hdl.handle.net/1843/61013-
dc.description.resumoPurpose To investigate and compare the demographic data, occurrence of recurrence and metastasis, and survival prognosis between ameloblastic carcinoma (AC) and metastasizing ameloblastoma (MA), based on appropriate and currently accepted eligible diagnostic criteria, in a systematic review of the literature. Methods An electronic search was undertaken, last updated in December 2021. Eligibility criteria included publications having enough clinicopathological information to confirm the diagnosis of these tumors. Results Seventy-seven publications reporting 85 ACs and 43 MAs were included. Both tumors were more frequent in mandible and showed different clinical profiles regarding patients' sex and age. There was no difference in the estimated cumulative survival between patients diagnosed with these tumors. Metastases mainly affected the lungs, followed by cervical lymph nodes. The mean time between the first metastasis and the last follow-up was higher for MA (p = 0.021). In addition, MA patients remained alive longer than AC patients after the first metastasis diagnosis (p = 0.041). Considering only the cases that metastasized, a higher ratio of AC patients died in comparison to MA patients (p = 0.003). The occurrence of recurrence was associated with a conservative primary treatment with both AC (p < 0.001) and MA tumors (p = 0.017). Multiple recurrent events were associated with conservative primary therapies with MA (p < 0.001) but not with AC (p = 0.121). Conclusion In addition to some demographic differences, ACs that metastasize present a worse prognosis than MA. As conservative procedures are associated with multiple recurrent events, this treatment modality should be avoided for both tumors.pt_BR
dc.description.sponsorshipCNPq - Conselho Nacional de Desenvolvimento Científico e Tecnológicopt_BR
dc.format.mimetypepdfpt_BR
dc.languageengpt_BR
dc.publisherUniversidade Federal de Minas Geraispt_BR
dc.publisher.countryBrasilpt_BR
dc.publisher.departmentFAO - DEPARTAMENTO DE ODONTOPEDIATRIA E ORTODONTIApt_BR
dc.publisher.initialsUFMGpt_BR
dc.relation.ispartofJournal of Oral Pathology & Medicinept_BR
dc.rightsAcesso Abertopt_BR
dc.rightsAtribuição-NãoComercial-SemDerivados 3.0 Portugal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/pt/*
dc.subjectAmeloblastic carcinomapt_BR
dc.subjectClinical featurespt_BR
dc.subjectMetastasizing ameloblastomapt_BR
dc.subjectOdontogenic tumorspt_BR
dc.subjectRecurrencept_BR
dc.subject.otherCarcinomapt_BR
dc.subject.otherAmeloblastomapt_BR
dc.subject.otherNeoplasiaspt_BR
dc.titleComparison of survival outcomes between ameloblastic carcinoma and metastasizing ameloblastoma: A systematic reviewpt_BR
dc.typeArtigo de Periódicopt_BR
dc.url.externahttps://onlinelibrary.wiley.com/doi/10.1111/jop.13334pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0002-3460-3374pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0002-6657-4547pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0002-7609-8804pt_BR
Appears in Collections:Artigo de Periódico

Files in This Item:
File Description SizeFormat 
Comparison of survival outcomes between ameloblastic carcinoma and metastasizing ameloblastoma_ A systematic review.pdf358.65 kBAdobe PDFView/Open
Show simple item record


This item is licensed under a Creative Commons License Creative Commons